APEl/Ref-1 (APEl), the mainmalian ortholog of Escherichia coli Xth, and a inultifw1ctional protein possessing both DNA repair and trai1scriptional regulatory activities, has a pleiotropic role in controlling cellular response to oxidative stress. APEl is the maii1 apurinic/ apyrin1idinic e11donuclease in eukaryotic cells, playii1g a ce11tral role in the DNA base excision repair pathway of all DNA lesions (uracil, alkylated and oxidized, ai1d abasic sites), including single-strand breaks, and has also cotranscriptional activity by modulating genes expression directly regulated by either ubiquitous (i.e., AP-1, Egr-1, NF-KB, p53, and HIF) and tissue specific (i.e., PEBP-2, Pax-5 and -8, and TTF-1) transcriptio11 factors. In additio11, it controls the intracellular redox state by inhibiting the reactive oxygen species (ROS) production. At present, ii1formation is still inadequate regarding the molecular mechmis1ns responsible for the coordii1ated control of its several activities. Both expression md/ or subcellular localization are altered in several metabolic md proliferative disorders such as in tumors md aging. Here, we have attempted to coalesce the most relevai1t information concemii1g APEl's different functio11s in order to shed new light md to focus current and future studies to fully understand this unique molecule that is acquiring n1ore and more interest and trai1slational relevance in the field of molecular medicii1e. Antioxid. Redox Signal.
C ELLULAR RESPONSE TO OXJDA TJVE STRESS is a highly regulated and complex biological process (42). APEl/Ref-1 (also called HAPl or APEX, and here referred to APEl), the mammalian ortholog of Escherichia coli Xth (exonuclease 111), is a vital protein that acts as an essential master regulator of this response, highly contributing to the maintenance of the genome stability. After cloning by h-vo independent groups in 1991 (21, 114) as a DNA repair enzyme first and as a red ox protein the following year (144) , APEl has been described, in -300 articles, as playing a role in several biologica I contexts. APEl is a dual function protein involved both in the base excision repair (BER) pathvvays of DNA lesions, acting as the major apurinic/ apyrimidinic endonuclease, and in eukaryotic transcriptional regulation of gene expression. This effect is obtained as a redox co-activator of different transcription factors such as the early growth response protein-1 (Egr-1), nuclear fac tor-KB (NF-KB), p53, hypoxia inducible factor-la (HIP-la), cAMP response element binding protein (CREB), activator protein-1 (AP-1), and paired boxcontaining proteins (Pax) in different cell systems (126) . These h-vo biological activities are located in h-vo functionally distinct domains. The N-terminus, containing the nuclear localization signal (NLS) region, is principally devoted to the redox activity, through Cys65, while the C-terminus exerts the enzymatic activity on the abasic sites of DNA (146) (Fig. lA) -
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Gpc -polymerase, PCIA, RFC (http://www.expasy.ch/ cgi-bin/blast.pl, accession number: P27695). While the C-terminal part of the protein is highly conserved during phylogeny, the N-terminus is not. Besides in the man1malian proteins, in which the N-terminus is highly conserved (> 90o/ o), this region is almost always absent in other organisms, with the exception of Zebra.fish, Drosophilil, Xenopus, and Dictyosteliun1, v.rhere homology is < 40°/o, suggesting that it may be a recent acquisition of evolution. The redox function of APEl is found only in mammals and not in other vertebrates, as demonstrated by the lack of redox function of the Zebrafish APEl (zAPEl). The acquisition of the redox function in APEl proteins is d iscussed in a recent publication (39). The two major functions of APEl, redox and repair, are completely independent in their actions, as shown by the observation that a mutation of the Cys at position 65 (C65) abolishes the redox function but does not affect the repair function (86) , whereas mutation of a variety of amino acids required for DNA repair activity, such as Histidine 309 (H309) and others (87, Vascotto et al.,  unpublished observations), do not affect the redox function. While the DNA repair active site of APEl has been clearly delineated (44, 90) , the redox domain is much less defined. The only Cys residue required for full redox function is C65, which is buried \·Vithin the APEl protein (44, 90), as recently confirmed by Georgiadis who mutated in the zAPEl a Thr (T58) to a Cys located at the same position of the Cys in the mammalian APEl, resulting in the acquisition of redox activity of the mutated protein (39).
The vital role of APEl seems to be due to its fundamental activity in the base excision repair (BER) pathvvay of DNA lesions (35). However, the biological relevance in eukaryotic transcriptional regulation of gene expression as a redox coactivator of different transcription has yet to be fully elucidated (126) .
Another interesting function is associated to its ability to indirectly bind to the negative calcium response elements (nCaRE) of some promoters (i.e., parathyroid hormone (PTH) and APEl promoters) acting as a transcriptional repressor. In particular, binding to nCaRE-B, in the PTH gene promoter, requires Ku70 (Ku86) as an additional factor in the complex (17) , while binding to nCaRE-B2 in the APEl promoter involves hnRNPL in teraction (77) . This activity seems to be regula ted by acetylation of APEl through the CBP /p300 HAT action (7) . A more recent finding has identified APE1's role in mediating production of single-strand DNA (ssDNA) breaks in gene promoters during repair of targeted base oxidation lesions caused by oxygen radicals generated during physiologic signaling (10, 153, 154) . Thus, defects in the APEl-mediated step in BER pathway could be Jinked to altered gene expression besides altering transcription factor state. This is discussed later in this review.
APEl subcellular distribution, in different mammalian cell types, is mainly nuclear and is critical in controlling cellular proliferative rate (35, 57, 67) . Interestingly, the expression of APEl is strictly connected to d ifferent tumorigenic processes (126) . The necessity of APEl for cellular survival and its frequent overexpression in tumor cells strongly suggest a fundamental role of this protein in preventing cell death and in controlling cellular proliferation. However, APEl abilities to activate transcription factors, such as p53 and Egr-1 (14, 30, 38, 54, 64, 107, 117) , mainly involved in controlling cell-cycle arrest and apoptotic programs, leave open the debate concerning the mechanisms responsible for controlling the different functions in several contexts. APEl protein is also localized within mitochondria in different cell types but, at present, the role in this organelle has not been completely elucidated (15, 88, 122) , as well as the molecular mechanism regulating its mitochondrial localization (15).
The fact that APEl is essential for cell viability was originally demonstrated by genetic studies. Knockout of APEl in mice causes postimplantation embryonic lethality on days ES to E9 (85, 147) , and attempts to isolate stable APEl-knockout cell lines were totally unsuccessful. For these reasons, a detailed comprehension of molecular targets of APEl func-603 tions has been very difficult. ln the last 3 years, conditional knockout and knockdovvn strategies (35, 67, Vascotto et al., unpublished observations) confirmed the crucial role of this protein for cellular existence and allo\.\red the establishment of cell models to better investigate and characterize the major functions of APEl. However, complete knowledge of molecular effectors regulated by APEl in determining its biological essentiality is still scanty. The necessity of APEl for mammalian cells seems to be mainly due to its DNA repair activity in BER pathway. Interestingly, attempts to restore the DNA repair activity in cells not expressing APEl, by using the yeast homologous Apnl (35) which Jacks the redoxtranscriptional activation domain, or an APEl mutant lacking the acetylation sites but not the DNA repair activity (67), or "''ith the redox-defective mutant C65S (Vascotto et al., unpublished observations) did not completely restore the loss of cell viability. Moreover, by specifically blocking the APEl redox but not DNA activity with an APEl -specific redox inhibitor, E3330, it has been shown that the cytokine-n1ediated hemangioblast development in vitro was significan tl y impaired (155) . Collectively, these data demonstrate that the exact knowledge of the precise molecular mechanisms for APEl's vital role in mammalian cells is still inadequate. They do, however, indicate that the repair function is crucial for survival and the redox function for cell growth (Vascotto et al., unpublished observations).
DNA Repair Activity of APE1
It is already 1~rel l established that a plethora of base lesions are induced in mammalian cell genomes by different physical and chemical agents, among which reactive oxygen species (i.e., 0 2 ·, I-1 2 0 2 and 'OH, collectively named ROS) play a dominant role. These lesions, if not adequately repaired, are at the basis of a variety of diseases (including cancer) and of aging.
The BER is the most used pathway to cope '~rith the single base lesion. The BER pathway is also involved in repairing the DNA single-strand breaks (SSB) induced by free radical agents. One of the key enzymes of the BER pathway in mammals is APEl. The basic reactions of the BER path\~ray have been extensively reviewed (26, 58, 81, 88, 126) . They require the coordinated activity of a number of enzymes including: (a) a DNA glycosylase capable of excising a specific modified base; (b) an AP endonuclease, such as APEl, which cleaves the S' phosphodiester bond, generating 3'0H and S'dRP termini; (c) an exonuclease activity (,8-polymerase, FEN, APEl); (d) a DNA polymerase (.B-polymerase, XRCCl or o Is-polymerase with PCNA); and, finally (e) a ligation activity (DNA ligases l and Ill, XRCCl), (Fig. lB) .The three ways by which APEl produces the 3'0H terminus for priming and the types of evolutionarily conserved amino acids necessary for these functions have been already reviewed (26, 58 and other articles in this issue of ARS).
All the steps of the BER pathway are finely orchestrated, both from the thermodynamic and the kinetic point of view, to provide an accurate repair of the damaged base and to avoid the generation of intermedia te products that are toxic for the cell (58) . This implies the coordinated interaction of the various players in the BER process and, when necessary, their further interaction with the DNA replication machinery, as demonstrated by the co-immunoprecipitation of the BER repair proteins with cyclin A and DNA replication proteins (103) . In this context, it is noteworthy that RP A proteins are able to suppress the APEl endonuclease activity in ssDNA of a replicative fork but not in a transcription bubble or in dsDNA (27) and that Cockayne syndrome B protein potentiates the APEl activity on ful ly paired AP-DNA but much more on bubble AP-DNA, suggesting a role for this protein in the transcription-repair pa th way (143) .
Of particular interest in the definition of new functions and targets of APEl is the finding that, after UV A irradiation, APEl co-localizes with Oggl in the nuclear speckles, organelles associated to transcription and RNA processing. This localization is abolished in the presence of antioxidants (12) , s uggesting that ROS are the driving force of this localization. Another interesting APEl function, connected to its capacity to bind to SSB, is that of inhibiting the same binding by PARPl, vvitl1 consequent inactivation of the poly-ADP-ribosylation and p revention of necrosis (121) .
A good exan1ple of how APEl m.ay use its dual nature to produce a cut in the DNA strand and to activate other proteins is that of the VEGF gene which contains a hypoxic response element (HRE) target of HIP-la. Oxygen deprivation induces formation of an abasic site in the response element follov.red by 1-IIF-la binding. The data suggest that the abasic site is the target of APEl activity with consequent increased flexibility of DNA which causes HlF-1 binding (10) and transcriptional activation of the VEGF gene (46, 153) .
Very recently, a role for APEl (and for APE2) has been suggested also in the antibody class switch recombination, where the abasic site generated by uracil DNA glycosylase, following cytosine deamination, is converted in a singlestranded break by a standard AP-endonuclease procedure (51) . Additionally, the recently found inhibitory crosstalk between the oncogene protein Bcl2 and the DNA repair activity of APEl (152), suggests a novel mechanism which may promote genetic instability and tumorigenesis.
Redox Regulation of Transcription Factors Activities
The intracellular redox status reflects the balance beh~reen the activity of antioxidant enzymatic and nonenzymatic cell systems (including GSH/GSSG, superoxide dismutase, catalase, peroxidases, glutathione peroxidases, etc.) and the amount of ROS produced: (a) as byproducts of respiration; (b) as a consequence of external noxious agents such as ionizing radiation; (c) as 'second messengers' (23, 42); and (d) during pathological states in activated neutrophils (93) . Of notice is the observation that variations in the redox state may result in alterations in gene expression profile asset. The molecular mechanism at the basis of this regulation is exerted through the modulation of transcription fa ctors (TFs) acti vity. In particular, the redox sta tus of reactive Cys residues, located w ithin the DNA-binding domain of some TFs, may control the transcriptional activity of the TFs itself. APEl has been identified as a protein capable of nuclear redox activity, inducing the DNA binding activity of several transcription factors, such as AP-1 (144), NF-KB (95), Myb (145), PEBP2 (1), 1-ILF (25), NF-Y (94), Egr-1 (14, 64), 1-UF-la (63), ATF/CREB family (145), p53 (38, 54, 117) , and Pax proteins (13, 128, 129) . In each case, this effect was accomplished TELL ET AL.
by maintaining the cysteine residues of the TFs in the reduced state (Fig. lC) , through a redox cycle in v.rhich Trx would restore the reduced form of APEl (61, 109, 132, 141 APEl functional activation is a consequence of different stimuli that may generate both physiological and toxic oxidative stress conditions or increase the intracellular cAMP levels leading to different outcomes (Fig. 2) .
The regulatory functions of the different APEl activities can be fine-tuned and implemented via three different mechanisms: (a) increase in APEl's level after transcriptional activation (107, 108, 111, 126) ; (b) relocalization of APEl from the cytoplasm to the nucleus (126) ; and (c) modulation of APEl's post-translational modifications (PTM), such as acetylation and phosphorylation. As recently demonstrated, in addition to redox regulation, acetylation appears to have a fine-tuning role in affecting APEl's different activities (7, 30, 67) .
Both in vivo and in vitro studies demonstrated that different oxidative or toxic agents and I or intracellular p roduced ROS effi cientl y and rapidly (within minutes to hours, depending on the specifi c ROS-generating stimuli) p romote a transient increase in APEl protein levels, which is inhibited by cyclohexirnide (111, 129) . Different transcription factors, including Sp-1 (36), Egr-1 (107), STAT3 (53), CREB (48), and Jun/ ATF4 (37) are involved in the inducible expression of APEl. APEl itself may inhibit its own expression through the binding to nCa-RE sequences within the APEl d istal promoter, thus constituting an autoregulatory functional loop (68) . In addition, APEl expression is linked in a positive autoregulatory loop with Egr-1 (107), and in a negative inhibitory loop with p53 (151) . Interestingly, p rotein upregulation is always associated with an increase in both redox and AP endonuclease activity, followed by an increase in cell resistance toward oxidative stress and DNA damaging agents (49, 87, 88, 111, 126) , strengthening the conclusion that an upregulation of APEl protein levels has profound biological consequences.
The activation of APEl is also obtained by a process independent from de nova synthesis and involves cytoplasm to nucleus translocation after exposure of cells to oxidative 
. ' DNA repair
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tin Intracell ular Ca++ ! stress conditions (111, 126, 127) or upon physiologic increase in intracell ular ROS production (108) . Nuclear localization of APEl is controlled by the first 20 amino acids at the N -terminal sequence, as determined by Jackson et al. (69) and nuclear import is controlled through a bipartite NLS comprising residues 1-7 and 8-13 with the involvement of an importin system. In fact, the first 20 residues directly bind to karyopherin al and a2. Data obtained by treatment of cells with the nuclear export inhibitor leptomycin B suggested the presence of a nuclear export signal (NES) that may reside in a Leu-rich region (L291, L292, L295 residues, which are exposed in the 3-D structure) (69) . Recently, it has been shown that the region comprising amino acids 64-80 contains a NES (110) . Thus, both n uclear import and export may control subcellu lar distribution of APEl. Tn addition, the interaction 1-vith specific n uclear proteins could be a means to maintain APEl within the nucleus. This hypothesis, recently proposed by Jung et al. based on their data showing that nuclear localization of APEl was dependent on GADD45a nuclear protein expression (71), deserves further experimental support.
·During the last few years, several lines of evidence have been accumulating, demonstrating that functional triggering of membrane-bound receptors (such as those for TSH, CD40L, ATP, IL-2, etc.) can lead to APEl functional activation through intracellular generation of sublethal doses of ROS (126) . Noteworthy is the observation that APEl is also directly responsible for the control of the intracellular ROS levels through its inhibitory effect on Rael (2, 52, 102, Vascotto et al., unpublished observations), the regulatory subunit of a membrane nonphagocytic NADPI-I oxidase system. This enzyme, composed of multiple membrane-associated (l\tlox and p22Ph 0 x) and cytosolic components (p67P 110 x, p47P 110 x, and Rael), catalyzes the transformation of the molecular oxygen to the superoxide anion by transferring an electron from the substrates NADH or NADPH (3). Since we have recently demonstrated that NADPH-mediated ROS production in-
Development of apoptosis Asbestos duced by P2Y triggering \.Vas able to promote APEl functiona 1 activation (108), we propose the existence of an autoregulatory loop between these two systems. This mechanism may be of therapeutic relevance for endothelial, fibroblastic, and smooth muscle cells, and should be analyzed in diseases of the v ascular system where an overactivation of the NADPH oxidase system is involved (19) , as well as in the angiogenesis process (133) , \vhere an additional autoregulatory loop between APEl and VEGF may be inferred (10, 153) . This observation could be therapeutically relevant in the treatment of tumor progression and cancer metastasis.
Based on the above-mentioned considerations, APEl seems to act as an intracellular signaling tool involved both in modulating the cellular response to acute and chronic oxidative stress conditions, and also in controlling the endogenous ROS levels during the physiological generation of ROS as intracellular signaling molecules. Since the cell system must be able to discriminate between different ROS-generating stimuli, APEl behaves as an integrating signaling molecule.
APEl is an abundant protein (-104-10 5 copies/cell) within eukaryotic cells and with a relatively long half-life
. Therefore, the fine-tuning of the multiple functions of this pleiotropic protein may reside in the impact tha t PTMs have on the function of APEl and on the modulation of the APEl-interactome under different conditions. Whereas for the forn1er hypothesis some experimental evidences have been obtained (acetylation of K6/K7 residues (7, 30)], very little information is no\v available on the protein interacting partners of APEl. Pioneering in silica studies discovered that several different phosphorylation sites were scattered throughout the molecule. These potential phosphorylation sites included consensus sequences for casein kinase I and II (CKI and CKII), for protein kinase C (PKC), and for GSK3 (Fig. lA) (34, 148). Initial in vivo studies confirmed a role for PKC in phosphorylating APEl in response to PMA or to alkylating agents (i.e., MMS) leading to AP-1 activation (62). 1-Iowever, these studies have not been repeated nor followed up. Therefore, the role of phosphorylation on APEl is still not clear.
APEl is a site for redox regulation by the dithiol-reducing enzyme Trx (61, 109, 132, 141) , through Cys35 and Cys32 in the catalytic center of Trx, and involving the Cys65 redox sensitive site of APEl (139, 141, 146) . The Trx-1nediated redox regulation of APEl is required for the functional activation of p53 (132) and AP-1 (61) . Though the biological relevance of Cys65 residue seems determined, it is not currently kno\<vn whether this Cys residue undergoes PTM in vivo.
Qu et al. (110) demonstrated that two (Cys93 and Cys310)
of the seven Cys residues of APEl can undergo S-nitrosation in response to nitric oxide stimulation, leading to nucleus to cytoplasm relocalization of the protein in a CRMl-independent process, possibly as a consequence of demasking a putative nuclear export signal (aa 64-80). S-ni trosation n1ay therefore constitute a specific molecular switch to strictly control the intracellular distribution of APEl between nucleus and cytoplasm, and provides a new working hypothesis for the cytoplasmic accumulation of APEl observed in more aggressive tumors (126) . Unfortunately, no detail is available about the functional implications of S-nitrosation on the different biological functions of APEl. Accordingly, since both NO and APEl are associated \.\Tith tumorigenesis and neurodegenerative diseases, future work is needed to address whether nitrosative stress leads to genomic instability, and may be the target for designing new therapeutic strategies. An interesting post-translational processing that has been recently described is proteolysis occurring at residue Lys31. This PT regulation of APEl protein is responsible for enhanced cell death mediated by granzyme A (GzmA) (29) and granzyme K (GzmK) (52) . APEl is associated \~Tith the endoplasmic reticulum in a macromolecular complex of 270-420 kDa containing evolutionarily conserved proteins called SET, pp32, and rlMG2. GzmA cleaves APEl after Lys31, giving rise to a protein form called N~33APE1, and alters its ability to be actively accumulated within nuclei of cells (15, 69, and our unpublished observations) and to interact \~Tith XRCCl (136) . Ho\.\1ever, some authors claimed tha t truncated APEl may loose its AP-endonuclease activity (29) and acquire a nonspecific DNAse function (150) . This peculiar processing is not limited to immune cells but may constitute a general molecular device for redirecting APEl to mitochondria (125) , as suggested by Chattopadhyay et al. (15) and Mitra et al. (88) , in spite of the intriguing finding of a proteolysis occurring at the level of Asn33 rather than Lys31. Again, if the removal of the terminal 31-33 amino acids is responsible for APEl to move to the mitochondria to function in mitochondrial BER as an AP endonuclease, it is hard to understand this truncated protein having nonspecific DNAse activity (150) unless it is ve1y cell-type specific. Accordingly, previous work by many investigators has never observed a nonspecific nuclease activity with the cleavage of the first 61 amino acids (66) and additional data clearly showed that the truncated APEl protein has an unaltered AP-endonuclease activity (15, and our unpublished observations), at least in vitro.
While it is known that nuclear accumulation of APEl triggers the activation of several transcription factors, the functional role of acetylation is barely understood. Acetylation TELL ET AL.
of both histones and regulatory proteins is commonly catalyzed by the histone acetyltransferase (HAT) p300/CBP, and can be reversed by histone deacetylases (HDACs), which in turn control the acetylation level of transcription factors or co-activators (50, 74) . Bhakat et al. have reported that the balance between the acetyltransferase activity of p300/CBP and the deacetylase activity of HDACl maintains APEl's acetyla tion at Lys residues 6 and 7 (K6, K7) in response to Ca 2 + levels, thus controlling expression of target genes (7). More recently, we found that exposure of 1-IeLa cells to I-1 2 0 2 and to histone deacetylase inhibitors increases acetylation of APEl at residues Lys6/Lys7, leading to Egr-1-mediated induction of the tumor suppressor PTEN gene expression (30) . Our data open ne\.\T perspectives in the comprehension of the many functions exerted by APEl in controlling cell response to oxidative stress and underline the double-face nature of APEl which plays a role in both pro-survival and in cell cycle arrest mechanisms. Interestingly, despite the very low homology degree in the N-terminal region (<40o/o), K6 or K6/K7 are much more conserved, thus reinforcing their primary role during phylogenesis.
Altogether, these observations have raised the possibility that subtle PTMs provide a means for channeling the multifunctional APEl to different activities and interactions and thus could act as a regulatory switch in performing different functions. APEl subcellular localization is quite variable. Most cell types exhibit only nuclear, others display only cytoplasmic, while others show both nuclear and cytoplasmic localization (126) . Such a complex distribution pattern suggests that localization is not random but, on the contrary, is controlled by a strictly regulated process. Though of fundamental interest for a full comprehension of the role of APEl in different pathological conditions, the clear understanding of the biological relevance of APEl subcellular compartmentalization still remains elusive. Whereas ,. ve can rather easily figure out the role for nuclear localization of APEl based on its main DNA repair and co-transcriptional activity, a convincing explanation for the extranuclear roles of APEl is still evanescent. Cytoplasmic localization of APEl, such as that reported for fibroblasts, spermatocytes, thyrocytes, lymphocytes, hepatocytes, and hippocampal cells (20, 22, 24, 72, 73, 112, 126, 129, 142) , is associated w ith high metabolic or proliferative rates and may be rela ted to a cell cycle-dependen t expression (36). Possible explanatory hypotheses for cytoplasmic expression of APEl may come from the mitochondrial role of the protein, as described above. A further functional explanation comes from its association with endoplasmic reticulum membranes, as evidenced by ultrastructural (125) and biochemical (28, 29, 47) analysis. It has been suggested that APEl redox activity in the cytoplasm may be required to maintain newly synthesized transcription factors in a reduced state during their translocation to the nucleus (24). Therefore, future work is required to shed more light on the extranuclear role(s) of APEl, starting from the explanation o f its cytoplasmic function.
Molecular Basis for the Vital Role of APE1 in Mammalian Cells: New Perspectives
To understand the vital role of APEl in mammalian cells, we recently combined gene expression array and proteomics analysis to identify the genes directly or indirectly regulated by APEl. By generating an inducible knockdown cell model, in which endogenous APEl expression could be inhibited by siRNA teclmology (Vascotto et al., unpublished observations), we built up the molecular nehvorks in which APEl is involved (see Fig. 3A , B, and C for models network). APEl silencing induces apoptosis through mitochondrial path\.vay and a strong inhibitory effect on cell growth. There is evidence of p53 activation and perturbation of the glucocorticoid receptor signaling pathway that could explain an induction of apoptosis. Glucocorticoid receptor NR3Cl (GCR-alpha) itself is do\~rnregulated, upon APEl silencing, whereas p53 is not. Instead, a large number of p53 controlled transcription factors are differentially expressed in our APEl silencing experiment, further supporting an important role of APEl in modulating p53 functions (38, 54, 117) (Fig. 38  and C) . Differentially expressed genes in our model strongly indicate a significant perturbation of the glucocorticoid receptor signaling pathvvay. Proteins of the HSP70 complex (i.e., HSPAlA, HSPAlB, and HSPA8) are significantly upregula ted as a consequence of APEl silencing, and it is known that HSP70 is required for the assembly of the glucocorticoid receptor-HSP90 complex (92) . Moreover, other key components and targets of glucocorticoid receptor signaling pathway were also on our gene list (Egr-1, C/EBPbeta, c-Myc, SUM0-4, 14-3-3 proteins, and tubulin proteins).
One of the genes that emerged from our analysis and is involved in the control of cell growth processes, as well as in the antioxidant response, is Egr-1. This transcription factor resulted as a good candidate target of APEl, since its expression was significantly reduced in APEl knocked-down cells both basally and upon serum treatment after starvation (Fig. 4A) . We therefore investiga ted the functional effect of APEl silencing in controlling the expression of one of the most well-kno\·vn Egr-1 target genes, the tumor suppressor PTEN, which is induced upon UV-and oxidative stress-cellular damage (5, 137). An impairment of Egr-1 expression upon APEl silencing affected the inducible expression of PTEN gene with a transcriptional mechanism, confirming the dual nature of APEl itself ( Fig. 4B and C) . Thus, the lack of APEl impairs the adaptive cellular response to damaging agents. These findings further enlighten the double nature of APEl to be involved in both the processes of cell growth and in gro1~1th arrest upon cellular damage. Interestingly, this kind of dual role nature in transcriptional regulation and DNA repair for proteins is consistently present in the five major DNA repair pathways, that is, homologous recombinational repair (HRR), nonhomologous end joining (NHEJ), nucleotide excision repair (NER), BER and mismatch repair (MMR), as in the cases of BRCAl, ATM, and p53 itself (for revie\.v, refer to Ref. 6). The existence and the correct regulation of a mechanism shifting cells from DNA repair to apoptosis is central to avoid progression to cancer, preventing clonal expansion of cells in which unrepaired damage would lead to mutation and to carcinogenesis. In this regard, it is interesting to note that a number of DNA repair genes (i.e., GADD45, BRCAl) were do1.vnregulated as a consequence of APEl silencing, suggesting the existence of a crossregula tion of the expression beh.veen individual partners of different pathways and underlining the central role of APEl in DNA repair processes with a different function besides the well-known AP-endonuclease activity. This hypothesis will require further investigation.
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The interesting finding that, besides its activity as a redox coactivator for Egr-1 transcriptional activity (64, 107) , APEl is also able to regulate Egr-1 expression levels reinforces the previously suggested hypothesis (107) of the existence of a functional loop between APEl and Egr-1 in reciprocally modulating each other. This finding strengthens the biological complexity typica l of this multifunctional protein and could well be a n1olecular tool by which APEl may regulate the expression of DNA repair genes such as GADD45 (130) .
Egr-1 activates the transcription of genes in response to a variety of mitogenic and nonrnitogenic stimuli, including growth factors and hypoxia (75) and it is able to form redoxmodulated transcriptional complexes with the AP-1 as \~rell as vvith APEl and Trx (76) . Accordingly, in line with the data obtained in our cell model, the role of Egr-1 seems to be pivotal. The central effect of APEl on Egr-1 biological functions is also reinforced by the concomitant downregulation of addi tional Egr-1 target genes such as C/EBP/3, VEGF and cMyc (Vascotto et al., unpublished observations; 135). Based on these findings the net\ovorking model depicted in Fig. 4D was assembled.
Future Perspectives in Elucidating the Pleiotropic Function of APE1 in Mammalian Cells at the Molecular Level. Looking at the Roles of the Mitochondrial and the Subnuclear Distribution of APE1. Could the N-Terminal Unconserved Domain Make the Difference?
As mentioned above, removal of APEJ NLS through proteolysis controls the amount of APEl present within the nuclear compartment and would constitute an elegant tool to control APEl alternative functions in noncanonical subcellular compartments, as mitochondria. Unfortunately, in nonimmune cells, neither the identity of the specific protease responsible for this cleavage nor the mitochondrial localization signal (MTS) have been determined yet. The relatively high molecular weight of APEl is not fully compatible with a passive mechanism of translocation through the outer membrane of mitochondria, and therefore it may require the presence of a specific regulatory transport mechanism. Whereas a large majority of proteins synthesized in the cytoplasm localize in to mitochondri.a by means of an N-terminal MTS, a significant fraction of mitochondrial proteins lack this recognition signal. In the case of APEl, it has been suggested that the MTS may reside in the C-terminal 69 amino residues of the protein (110) . Mitochondrial localization of APEl may be associated to a potential role in DNA repair of oxidized bases in the mitochondrial genome (15, 88, 126). However, since it is not clear whether, in vivo, NC.33APE1 maintains its DNA repair activity (29) or, as previously suggested, may acquire an aspecific endonuclease activity for dsDNA in vitro (150) , at present it is impossible to derive any definite conclusion. Moreover, since generation of truncated NC.33APE1 form is associated with the occurrence of an apoptotic phenotype (52; Vascotto et al., unpublished observations), it cannot be excluded that this APEl form may be causatively involved in the cytotoxic effect driving pro-apoptotic triggering directly from mitochondria. Preliminary data obtained in our laboratory in cells expressing a noncleavable mutant APEl protein (i.e., 31-34A mutant) seem to support this hypothesis. Should this be confirmed, strategies to modulate the pro- teolytic removal of the APEl N-terminus will constitute a possible good candidate target for future drug development. On the other side, it is not completely clear whether truncation of APEl N-terminus may affect APEl redox activity (29, 52) , leaving open the debate on the biological meaning of the process. Since the N-terminal region of the protein seems to be a result of phylogenetic evolution, it is intriguing that this part of the protein could account for the difference in modulating the various functions of APEl.
In addition to the canonical 37 kDa APEl protein, and the truncated Nt.33APE1 form, in some circumstances the appearance of a lovver mobility band of -SO kDa has been detected (our unpublished data). This form vvould account for a PTM that introduces a substantial modification to the wildtype protein. A recently identified PTM, typically occurring on Lys residues of several nucleoproteins, is sumoylation (40, 56). The addition of a small ubiquitin-like modifier (SUMO) molecule to the target p rotein accounts for an increase of -12 kDa of the apparent molecular n1ass of the target protein itself. Many SUMO-modified proteins function in regulation of transcription, chromatin structure, maintenance of the genome stability, and signal transduction. Upon sumoylation, interactions that are dependent on other post-translational modifications or on unmodified lysine are lost. Sumoylation also promotes novel interactions, in some cases associated with a conformational change in the target protein. The effects of PTM by SUMO to compete for target lysines enhance or inhibit interactions '~'ith other proteins (or other binding partners, such as DNA) or induce conformational changes. These effects are not mutually exclusive, but might not all occur on the same substrate. Thus, we investigated the possibility tha t APEl may undergo sumoylation. APE1 protein contains 29 Lys residues, 15 of them lie in the N-te1minal domain, and 14 residues lie in the C-terminal domain of the protein. Protein sequence analysis using three different softwares for prediction of sumoylation sites (SUMO Plot, SUMO sp, and SUMO PSFS) revealed several "low probability" putative sumoylation sites and a "high probability" putative sumoylation site, \-vhich contains a canonical sumoylation 1/J-K-X-D IE motif (Fig. SA and B) . Putative sumoylation sites do not distribute homogenously along the whole sequence, but concentrate at the N-terminal domain, which is not presen t in functionally related proteins from other organisms and is required for the redox acti vity of APEl. Co-localization experiments on cells transfected with GFP-SUM0-1 clearly demonstrated that endogenous APEl can be modified by wild-type SUM0-1 but not by a deletion mutant (i.e., t.6SUM0-1), which looses its ability to modify target proteins (Fig. SC) . Jn vitro sumoylation experiments also clearly demonstrated that APEl may undergo sumoylation (unpublished data). Our inability to identify the Lys residue target of sumoylation, by mutagenizing the putative sumoylation sites identified during in silica analysis (unpublished data), may suggest that multiple Lys residues could be the simultaneous target of this PTM. Additional work, which is difficult as sumoylated APEl represents a very tiny fraction in comparison to the nonsumoylated protein, is required to understand the role of sumoyla ti on in controlling APEl functions.
In summary, all of these studies have confirmed the dual role nature of APEl, as a prototypical example of an apparent biological paradox. While a number of reports clearly TELL ET AL. demonstrated the antiapoptotic roles as well as the positive effect on cell proliferation (for a review, see Ref. 126, and 35, 67, 88) , other data underlined its potential role in controlling proapoptotic functions through pS3-mediated activation of p21 (38, 54, 117), leading to the arrest of cell cycle by inhibiting cyclin-dependent kinase function (11 ) , and cyclin G, having pro-apoptotic activity (97) . However, it is becoming increasingly evident that the antiapoptotic roles of APEl are ascribable to its DNA repair functions (35) rather than to its activities as a transcriptional co-activator. Thus, it is tempting to speculate that the latter function-activation of transcription factors (i.e., p53 and Egr-1) ensuring efficient cellcycle arrest-may act in concert with the previous (repair of DNA damage) to protect cells from accumulation of oxidative damage (Fig. 6 ) and be a later evolutionarily acquired function since only mammals and not just vertebrates appear to have the redox signaling function (39). This may have been an advantageous addition to APE1's interactions and functions that benefi ted mammalian cells, given the potentially toxic nature of their environment. This may have subsequently led to additional signaling and regulatory interactions and func tions. Obviously, for a proper modulation of these two interconnected functions, a fine-tuned regulation of APEl activities is required. Thus, a better understanding of the processes controlling APEl subcellular distribution, of the post-translational modifications occurring on the protein itself, of the mechanisms controlling protein half-life, and of the different interacting partners recruited as a function of cellular response, is required to fully address this paradoxica I issue.
Clinical Perspectives: Altered Expression/Distribution of APE1 and Human Pathology
Accumulating evidence has demonstrated that the heterogeneity of APEl expression pattern is linked to different pathological conditions ranging from metabolic to differentiative disorders, including cancer and neurodegenerative diseases. Different kinds of human tumors were characterized by alterations in subcellular distribution of APEl with respect to nontumoral tissue (73; for review, see 126). Generally, APEl localization is eminently nuclear, while in several carcinomas a nuclear, cytoplasmic, and nuclear I cytoplasmic staining was observed (126) . This peculiar distribution correlates well with the aggressiveness and prognosis of the tumor as nuclear localization was always associated with a better prognostic feature together with a higher degree of cellular differentiation, low angiogenesis, and negative lymph node status. As in hepatocellular carcinoma (HCC), a cytoplasmic localization of APEl was associated with a significant lo,-ver degree of differentiation and with a shorter survival time, the localization of APEl in liver biopsy is of prognostic value (22). Noteworthy, alteration in subcellular distribution of APEl is not functionally related to the ability of cancerous tissue to repair a basic sites, suggesting that DNA repair by BER may not be affected (8, 113, 115) . Therefore, it appears that the extranuclear roles of APEl are responsible for its association with cancer.
\.Vhether the alterations of APEl subcellular localization are causally responsible or only associated with tumor progression is not clear at present. However, our recent findings in HCC, in which a chronic cellular oxidative 
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Motifs with low probability 611 318 FlG. 5. (A) APE1 protein sequence bears several putative sun1oylation si tes, as fron1 in silica analysis. APE1 protein contains 29 Lysine residues, 15 of them lie in the N-terminal domain of the protein. Protein sequence analysis using three different softwares for prediction of sumoylation sites (SUMOPlot, SUMO sp, and SUMO PSFS) revealed several "lovv probability" putative sumoylation sites and a "high probability" putative sumoylation site, vvhich contains a canonical sumoylation ~1-K-X-D/E motif. Putative sumoylation sites do not distribute homogenously along whole sequence, but concentrate at N-terminal domain, vvhich is not present in functionally rela ted proteins from other organisms and is required for the redox activity of APEl. (B) Of the 29 Lys residues, 8 of them are identified as potential surnoylation sites vvith the three different softwares. Lys85represents a classical consensus sequence, recognized by all progr ams. Lys78 is recognized as low-probability consensus sites by two different programs, while five Lys residues (K3, K6, K27, K63, and Kl25) are recognized as potential sumoylation sites by only one program. Interestingly, all potential sumoylation sites reside within the Redox transactivation domain. (C) APEl colocalizes with SUM0-1, but not with ~6 SUM0-1, into nuclear subdomains, presumably nuclear bodies. HeLa cells were transfected with either pGFPSUM0-1 or pGFP~6SUMO-l, as a negative control. The inactive ~6SUM0-1 is a deletionmutant lacking the 6 C-terminal aminocid residues, including double glycines being the site for the isopeptidic bond with the target protein, whichcannot sumoylate target proteins located in the nuclear bodies. Thus, this mutant relocalizes within nucleus and cytoplasm in a diffuse way. APEl staining vvas analyzed using a monoclonal anti-APEl antibody. Primary antibody and GFPSUM0-1 staining were revealed by incubation with Alexa Fluor 546 conjugated secondary antibody or by intrinsic green fluorescence of GFP, respectively. Merging of the two colors results in a yellow signal, co1Tesponding to co-localized proteins. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at www.liebertonline.com/ars). Thus, APEJ seems to play also a leading role in the production of inflammatory cytokines. Fu ture work will be needed to extend these observations and to open new applicative perspectives in molecular medicine.
Other than in proliferative disorders mentioned above, APEl deregulation has also been demonstrated in other pathologies, in particular degenerative disorders. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), are characterized by a condition of chronic oxidative stress that primarily contributes to the pathogenesis through apoptosis of neuronal ce.lls (33). APEl is highly expressed in selected regions of the central nervous system (99, 100, 142) . A reduction in APEl expression, followed by an increase in the apoptotic rate, occurs in the hippocampus after a hypoxic-ischemic injury (41), in the cortex after compression injury (79) , and in the spinal cord after ischemia (116) . The hippocampus of patients with Alzheimer shows an increased expression of APEl levels in senile plaques and plaque-like structures (123) . Our recent unpublished data demonstrated an increased nuclear expression of APEl in neuronal and glial cells of the cerebral cortex in both familial and sporadic Alzheimer (Marcon et al., unpublished data). These findings, together with the observation of an increased DNA repair mechanism in Alzheimer {18), may be associated with the cellular adaptive response to the oxidative stress condition typical of Alzheimer, and may be involved in the pathogenesis of the disease. Despite the abundance of APEl in neurons and the correlations between alterations in APEl levels and various neuropathologies, few studies have addressed the role of APEl in preventing neurotoxicity. Recent data demonstrate that APEl protects primary cultures of hippocampal and sensory neurons from oxidative damage induced by H 20 2 (134). However, despite its fundamental importance for future therapeutic development, the p recise mechanism o f the protective effect is still poorly unders tood.
Translational, Clinical Applications of APE1 Redox Inhibition for Cancer or Other Areas
As discussed in the previous sections, APEl has two primary and major activities: DNA BER and redox signaling of downstream transcription factor targets. While previous studies have de1nonstrated that altering APEl levels leads to blockage of cell growth and increased cancer cell sensitivity (8, 9, 16, 26, 31, 32, 55, 59, 65, 78, 80-83, 87, 98, 120, 124, 131, 138, 140, 149) , these studies have either used overexpression of APE1, APEl antisense oligonucleotides, or APEl siRNA. The dilemma with this approach, \.vhile valid, is that each of these procedures changes the total cellular content level of APEl and removes all of APEl's functions, not just the repair or redox activities. Because APEl has multiple functions, as well as interactions with many other proteins (belonging to DNA repair, signaling and to the Egr-1 pathway), the increase or decrease of APEl protein may result in multiple effects in which the APEl's specific role cannot be easily de-picted. Furthermore, recent studies tested the hypothesis that APEl is responsible for mediating production of singlestrand DNA (ssDNA) breaks in gene promoters during repair of targeted base oxidation lesions caused by oxygen radicals generated during physiologic signaling (10, 153, 154) . Production of ssDNA breaks is believed to play a key role during transcription by imparting substantial flexibility to promoter sequences, enabling them to bend in a manner that establishes the chromatin architecture needed for gene expression. In addition, APEl, besides forming the ssDNA break, is also required for high-fidelity repair of the break (104, 105, 119) . Thus, defects in the APEl-mediated step in BER pathway could be linked to altered gene expression besides altering transcription factor state.
Use of specific small molecule inhibitors, such as one that blocks APEl redox, but not repair, will be important to delineate the distinct roles of APEl in various cancers, other diseases, and normal cellular functions . Likewise, an APEl specific repair inhibitor will help to elucidate that role (4). Ultimately, using APE1 redox inhibitors w ith APE1 specific endonuclease repair inhibitors will give a clearer picture of the multiple activities of APE1.
APEl \.Vas 01iginally identified as the primary target of E3330 (3-(5-(2,3-dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonyl-2-propionic acid), a small molecule redox inhibitor (155) . £3330 was immobilized on beads and APEl was identified from a nuclear extract of a leukemia cell line as a protein that specifically bound to E3330. Using surface plasmon resonance (SPR), an equilibrium constant (Ko) of 1.6 nM was obtained for the binding of E3330 to APEl, suggesting a specific interaction. E3330 was also shown to block the ability of APEl to reduce NF-KB, thus interfering with the redox activ ity of APEl (45, 60, 89, 118) . The proposed binding site on APEl is somewhat puzzling. The amino acid residues 72-80 form a ridge on the surface of the molecule with no obvious cavities or binding pockets that are large enough to bind E3330. Currently, we are pursuing studies to delineate the binding site or region of £3330 on APEl.
Our recent data have demonstrated that E3330 blocks the redox function of APEl with AP-1 as the downstream target in vitro (86) . Additionally, using a transactivation assay for AP-1 or HIF-la targets in ovarian cancer cells, increasing amounts of E3330 Jed to decreased activation of a luciferase reporter downstream of AP-1 and HIF-la (86) . While E3330 blocked APEl's redox function, it had no effect on APEl repair endonuclease activity nor other members of the BER pathway (86) . These studies demonstrate the specificity of E3330 for APEl's redox, but not for its repair function. This is supported by our recently published data in ovarian cancer studies in xenografts demonstrating that the knockdov.rn of APEl results in the blocking of cell gro,.vth and proliferation, but not necessarily cell death (31). This is the first time that cancer cell killing has been reported using a small molecule inhibitor of APE1 redox function. E3330 \.vas also shown to have single agent inhibition of cell growth using a variety of cancer cell lines including, ovarian, colon, lung, breast, brain, pancreatic, prostate, and multiple myeloma cancers (Kelley et al. unpublished observations). In stark contrast, we do not see significant growth inhibition in our studies with normal cells such as hematopoietic embryonic cells (155) Additionally, an in vitro angiogenesis assay was also used to determine the effect of £3330 on RVEC formation of capillary-like structures on Matrigel. The inhibitory effect of E3330 was similar to the proliferation assay \.Vith the complete loss of tube formation at low micromolar concentrations. These results demonstrate that blocking APEl's redox function attenuates RVEC proliferation and capillary formation 'in vitro and these findings implicate the use of an APEl redox inhibitor in antiangiogenic translational studies. Further mechanistic studies as to how this is occurring are in progress, although prelin1inary studies indicate the redox inhibitory effect is not necessarily related to cell killing, but to a block in cell proliferation or cytostatic effect similar to that observed using APEl siRNA in vivo (31).
In conclusion, APEl is a multifunctional protein with both important DNA repair and redox capabilities. However, in order to demarcate the various functions of APEl, small molecule inhibitors of each function will be necessary to ultimately conclude \.vhich function is required in normal and cancer cell function. Recent findings with redox inhibition of APEl have potential clinical translational significance such that a redox inhibitor could be used as a single agent, in combination \· vi th current trea tments or as a potential antigrowth, cytostatic agent. Furthermore, new APEl redox analogues could play a role in antiangiogenic therapies. 
